Forest Laboratories Aiming To Market Escitalopram For Depression Treatment

OPEN MINDS, The Behavioral Health & Social Service Industry Analyst Industry News On March 26, 2001, Forest Laboratories Inc. announced that it submitted a new drug application with the US Food and Drug Administration (FDA) to market Escitalopram for the treatment of depression. Ken Goodman, president and chief operating officer of Forest Laboratories, says the new antidepressant drug is more potent than the company's drug, Celexa. He says Escitalopram has good potency and few side effects. This drug is the single isomer version of Celexa and is a more selective seratonin inhibitor for the treatment of depression. Mr. Goodman . . .